Check for updates

OPEN ACCESS

EDITED BY Gaetano Gallo, Sapienza University of Rome, Italy

REVIEWED BY George Pappas-Gogos, Democritus University of Thrace, Greece Pietro Fransvea, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Italy Nunzio Velotti, University of Naples Federico II, Italy

*CORRESPONDENCE

Xiangquan Lai 1587415141@qq.com Tianbao Xiao prof_xiaotianbao@163.com

SPECIALTY SECTION This article was submitted to Surgical Oncology, a section of the journal Frontiers in Oncology

RECEIVED 08 August 2022 ACCEPTED 03 October 2022 PUBLISHED 26 October 2022

CITATION

Deng J, Hu W, Li Y, Xiong K, Yue T, Lai X and Xiao T (2022) Meta analysis of indocyanine green fluorescence in patients undergoing laparoscopic colorectal cancer surgery. *Front. Oncol.* 12:1010122. doi: 10.3389/fonc.2022.1010122

COPYRIGHT

© 2022 Deng, Hu, Li, Xiong, Yue, Lai and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s)

are credited and that the original official publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Meta analysis of indocyanine green fluorescence in patients undergoing laparoscopic colorectal cancer surgery

Jia Deng¹, Wenting Hu^{1,2}, Yang Li^{2,3}, Kai Xiong¹, Tinghui Yue¹, Xiangquan Lai^{3*} and Tianbao Xiao^{3*}

¹College of Clinical Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang, China, ²College of Pharmacy, Dali University, Dali, China, ³Colorectal and Anal Surgery, The First Affiliated Hospital of Guizhou, University of Traditional Chinese Medicine, Guiyang, China

This meta-analysis intended to systematically evaluate the clinical implications of indocyanine green fluorescence (ICG) in patients undergoing laparoscopic colorectal surgery. PubMed, MEDLINE, Cochrane Library, EMBASE, China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Medical Information System and China Biomedical Database were synthetically searched for studies published from inception to April 14, 2022. The randomized controlled trials comparing ICG-use with controls were selected. The incidence of anastomotic leakage (AL), lymph node detection, operation duration, intraoperative bleeding, postoperative morbidity, and hospitalization time were evaluated in summary analysis, and calculated the corresponding 95% confidence intervals (CI). Subsequently, in addition to subgroup analyses, studies for heterogeneity, sensitivity, and publication bias were carried out. Consequently, 3453 patients in the enrolled 15 studies were included; 1616 patients were allocated to the experimental group, and 1837 patients were assigned to the control group. The ICG group had a significantly decreased risk of AL (RR: 0.50, 95% CI: 0.37-0.67) and shorter hospitalization time (SMD: -0.31, 95% CI: -0.54-0.08) compared to the control group. Meanwhile, the ICG showed clearly better lymph node detection (SMD: 0.19, 95% CI: 0.02-0.36). However, when the content of operation duration (SMD: -0.07, 95% CI: -0.30-0.15) and intraoperative bleeding (SMD: -0.16, 95% CI: -0.35-0.04) were compared, no statistical significance was found. Furthermore, the pooled analysis of postoperative morbidity was not statistically significant (RR:0.79, 95% CI: 0.58-1.08). The results of the subgroup analysis of AL indicated that there may be regional variations in AL (RR: 0.50, 95% CI: 0.37-0.67) but not in postoperative morbidity (RR: 0.79, 95% CI: 0.58-1.08). In conclusion, the application of ICG in laparoscopic colorectal surgery can effectively reduce the AL, lymph node detection, and hospitalization time. However, more multicenter large-sample randomized controlled trials are required to further confirm its advantages. The meta-analysis was registered in PROSPERO (no. CRD42022288054).

KEYWORDS

indocyanine green, laparoscopic surgery, meta-analysis, colorectal cancer, systematic review

Introduction

Colorectal cancer (CRC) is one of the most prevalent gastrointestinal malignancies with high incidence and mortality, seriously threatening human life and health. The latest global statistics show 1,148,515 new cases of colon cancer and 732,210 new cases of rectal cancer in 2020, with a 9.4% mortality rate for CRC patient (1). In addition, mortality from CRC is projected to increase significantly by 71.5% (rectal cancer) and 60% (colon cancer) in 2035 (2). In the Chinese population, CRC is also one of the most common cancers and has shown a pattern of increasing incidence and mortality rates over time (3). Radical surgery (R0/R1 resection) remains to be a primary procedure for the management of CRC and recommended by the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines. Laparoscopic colorectal surgery has become a standard and mainstay operation for the treatment of localized CRC with the continuous development of minimally invasive technology (4, 5). In comparation with open abdominal surgery, laparoscopic surgery has significant advantages, such as minimally invasiveness, little bleeding, quickly postoperative recovery and improvement in patient care quality. However, the blindness of lymphatic clearance and the inability to touch become the biggest challenges to be solved in the laparoscopy. Furthermore, the technical challenges of laparoscopic surgery for CRC also have been raised by robotic technology with advantages of articulating wrists, lack of hand tremors, and decreasing the learning curve (6). Therefore, an auxiliary technology is urgent for laparoscopic colorectal surgery to improve its precision and individuality.

Indocyanine green (ICG) is a near-infrared light contrast agent with good biocompatibility. It is excited by external light at a wavelength of 750–800 nm, and in-turn emits near-infrared light of a longer wavelength for visualization of tissues and organs (7). Since Nagata first applied ICG in colorectal surgery in 2006, considerable research value and good application prospects in the adjuvant diagnosis and therapy of CRC have been demonstrated by this technology (8–12). More and more attention has been paid to the role of ICG in laparoscopy, including the accurate intraoperative localization of the tumor and the rigorous cleaning of the lymphatic drainage area. In addition, since ICG can be used to observe the intestinal blood supply at the anastomosis, it has significant practical advantages in lowering the incidence of postoperative anastomotic leakage (AL) (13). However, this technique is still in the exploratory stage in the diagnosis and treatment of CRC, so there are no standardized application criteria and operation specifications, and few guidelines and consensus for reference. Systematic observation and analysis are lacking in the application value of ICG. In this study, we will investigate the efficacy of ICG in laparoscopic colorectal surgery and provide reliable evidencebased medical evidence for its wide application in clinical practice.

Materials and methods

Protocol registration

This agreement was previously registered in PROSPERO in December 2021. (Number: CRD42022288054, https://www.crd. york.ac.uk/PROSPERO/display_record.php?RecordID=288054).

Qualification criteria

The Cochrane Handbook for Systematic Reviews of Interventions and the PRISMA Statement were consulted for this study. Meanwhile, the "PICOS" principles were used as a guide for this study's inclusion and exclusion standards. Studies must meet the following inclusion criteria: (i) Patients with laparoscopic colorectal surgery for CRC (including colon and rectal cancer) were of different sex, age, race, and nationality. (ii) The experimental group was allocated in laparoscopic colorectal surgery by ICG, while the control group was assigned in laparoscopic colorectal cancer without ICG. (iii) The effectiveness between conventional laparoscopic colorectal surgery and laparoscopic colorectal surgery with ICG was compared. (iv) At least one of these outcome indicators must be reported, including the main outcome indicators such as AL and lymph node detection. The secondary outcome indicators include postoperative morbidity, operation duration, hospitalization time, and intraoperative bleeding. (v) The design of these studies were prospective randomized controlled trials (RCTs). Studies were asked to meet the following exclusion criteria: (i) Full text or specific values of the required indicators were not available. (ii) Comparison of the efficacy of two procedures was not included; (iii) duplicate publications; (iv) case reports, conference reports, reviews, animal experimental papers, and meta-analysis.

Search methodology

Two researchers conducted a search in the following databases: pubMed, MEDLINE, Cochrane Library, EMBASE, China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Medical Information System, and China Biomedical Database (CBM). Meanwhile, the period was limited from the database's creation until April 14, 2022. The search terms were composed of the following medical themes (MeSH) and additional conditions: (colorectal cancer/colorectal neoplasms/colorectal tumor) AND (indocyanine green/ fluorescence/spectroscopy near-infrared) AND (randomized controlled experiments/clinical trials). Furthermore, manual studies would be conducted to find potential references. Language was not an obstacle to publication.

Research selection

The program EndnoteTM, Version X8 (Thompson Reuters) was used to combine all search results. Repeated studies were manually removed. Two researchers independently screened the original studies and then read the full text to select the literature that met the inclusion criteria. Disagreements should be settled through discussion or by reaching an agreement with a third party.

Data selection and analysis

The data extraction was completed independently by two researchers who cross-checked the results using a uniform data extraction form. The following information was included in the data extraction: (i) The research ID, including the first author's name and publication date. (ii) The research participant, including the number and age of the participants. (iii) The treatment program for the experimental and control groups. (iv) the main outcome indicators, such as AL and lymph node detection, and the secondary outcome indicators included postoperative morbidity, operation duration, hospitalization time, and intraoperative bleeding. The original author was contacted if the necessary information was not available, and the data was considered missing if there was no response. Furthermore, the disagreements between two researchers were settled through discussion or consensus, and a third researcher was requested to solve the conflict if required.

Quality evaluation

The quality of the included studies was evaluated by two researchers independently, and conflicts among them were resolved through discussion or third-party consensus. Risk bias assessments were produced using RevMan 5.3 software based on the Cochrane Risk of Bias Assessment Tool. The evaluation included the following seven major components: random sequence generation; allocation concealment; blinding of patients and testers; blinding of outcomes assessors; incomplete results; selective reporting; and other bias (such as potential bias related to special research design, declaration of fraud, etc.). Finally, judgments should be made in this study, such as "low bias risk," "high bias risk," and "uncertain bias risk."

Data analysis

The data was statistically analyzed using Stata 14.0 (Stata Corporation). Relative risk (RR) and standardized mean difference (SMD) were used as effect statistics for dichotomous and continuous variables, and 95% confidence intervals (CI) were calculated. The I^2 test was initially used to investigate heterogeneity. If $P \ge 0.1$ and $I^2 \le 50\%$, heterogeneity between studies was small and a fixed-effect model was used; if P < 0.1 and $I^2 > 50\%$, heterogeneity existed between studies and a random-effect model was used for meta-analysis. Subgroup analysis was carried out based on the various included study areas, and sensitivity analysis was carried out using the leave-one-out method for outcome indicators with high heterogeneity, as well as the contour-enhanced funnel plot.

Result

Literature selection results

Initially, 523 potentially relevant papers were screened, and 50 duplicate items were completely removed. Furthermore, 423 papers were excluded after reading the titles and abstracts because they were not suitable for the inclusion criteria. 35 articles were retained after carefully reviewing the abstracts and full texts of the remaining 50 articles. Finally, 15 studies were enrolled after rigorous screening using inclusion and exclusion criteria (Figure 1).



Study characteristics

A total of 3453 individuals (14–28) were enrolled in 15 included studies; 1616 of these patients were in the ICG group and 1837 were in the control group. The fundamental features of all included studies were displayed in Table 1. ICG was administered through an intravenous injection (IV) in 12 trials (14, 15, 17–21, 24–28) and as a submucosal injection in 3 trials (16, 22, 23). The AL result was reported in 10 trials (14, 15, 17–21, 25, 27, 28). There were 5 trials that reported lymph node detection (22–24, 26, 28). Postoperative morbidity was observed in 8 trials (14–16, 22–24, 26, 28). Operation time was reported by 9 trials (16, 21–28), hospitalization time was reported by 8 trials (16, 19, 21–24, 26, 28), and intraoperative bleeding was reported by 7 trials (21–24, 26–28).

Quality evaluation of included studies

The methodological quality assessment of the 15 included studies was displayed in Figure 2. The formation of random sequences was fully recognized in all of the selected studies, as shown in Figure 2A. Meanwhile, allocation concealment was ambiguous. None of studies mentioned the application of blinding, and the evaluation of performance bias was regarded as high risk (Figure 2B). There were no studies with incomplete or biased results. The methodological quality of all selected studies remained low due to the complete lack of blinding.

Evidence quality

The GRADEpro, which was developed by the Cochrane Collaboration Network, was used to assess the quality of evidence. A classification of the evidence was made for these studies and based on their limitations, inconsistencies, indirectness, imprecision, and publication bias. The quality of the evidence was classified as high, moderate, low, or very low. The quality of evidence was moderate for these outcome indicators due to a lack of blinding in RCTs. The profile of GRADE evidence was displayed in Figure 3A, and a detailed summary of the findings was shown in Figure 3B.

Meta-analysis of AL

Heterogeneity was examined first before the pooled analysis. Ten studies displayed low significant heterogeneity (P=0.405, I^2 = 3.9%) so a fixed-effect model was used to combination. The result showed a significantly lower incidence of AL [RR=0.50,

Research ID	Sample number (n)		Ages (year)		Tumor types	Dose of ICG	Route of	Outcomes
	study	control	study	control			medication	
Alekseev M (14)	187	190	Range:21-86	Range:66-85	CRC	0.2 mg/kg	iv	13
De Nardi, P (15)	118	122	Range	e: 29-88	CRC	0.3 mg/kg	iv	13
Park JH (16)	114	228	67.91 ± 8.94	66.81 ± 10.18	CRC	0.5-1 ml	submucosal injection	345
Ishii M (17)	223	265	Range:30-90	Range:27-93	CRC	5 mg	iv	1
Bonadio L (18)	33	33	71.85 ± 11.1	69.03 ± 11.3	CRC	0.2 mg/kg	iv	1
Kin C (19)	173	173	58.2 ± 13.2	58.1 ± 13.2	CRC	3 ml	iv	15
Ren P (20)	63	82	1	NR	CRC	2.5 mg/ml	iv	1
Wu G.C (21)	130	130	66.63 ± 4.72	67.53 ± 4.59	CRC	2.5 mg/ml	iv	1456
Zhang J.F (22)	68	77	60.2 ± 12.5	58.4 ± 14.1	CRC	2.5 mg/ml	submucosal injection	23456
Zhou SC (23)	12	30	60.3 ± 9.6	58.5 ± 9.5	RC	0.1 mg/ml	submucosal injection	23456
Su H (24)	84	105	59.1 ± 11.1	60.2 ± 9.8	CC	3 ml	iv	23456
Tsang YP (25)	62	69	69.82 ± 9.89	67.71 ± 11.65	CRC	10 mg	iv	14
Ge L (26)	36	22	56.4 ± 9.6	58.1 ± 11.0	CC	3 ml	iv	23456
Foo CC (27)	253	253	66.6 ± 10.6	67.2 ± 11.0	CRC	5 mg	iv	146
Jing D.S (28)	60	58	56.7 ± 7.42	54.4 ± 7.64	CC	2.5 mg/ml	iv	123456

TABLE 1 Basic characteristics of the included studies in the meta-analysis.

NR, not reported; IV, intravenous injection; (1), AL; (2), Lymph node detection; (3), Postoperative morbidity; (4), Operation duration; (3), Hospitalization time; (4), Intraoperative bleeding.

95% CI (0.37–0.67), Z=4.49, P=0.000] in the ICG group. Meanwhile, a subgroup analysis of AL was conducted by different regions. The studies were divided into two subgroups based on their geographical location: Asia and Europe/America. Four studies were reported from Europe/America [RR=0.64, 95% CI (0.44–0.95), Z=2.25, P=0.025] and six from Asia [RR=0.34, 95% CI (0.21–0.57), Z=4.11, P=0.000]. The subgroup analysis revealed statistically significant differences [RR=0.50, 95% CI (0.37–0.67), Z=4.49, P=0.000] across regions (Figure 4).

Meta-analysis of postoperative morbidity

The test of heterogeneity in the pooled analysis was examined first, and there was no significant heterogeneity (P=0.970, $I^2 = 0.0\%$) in the eight studies. The pooled analysis of postoperative morbidity was performed by a fixed-effects model, and there was no statistically significant [RR= 0.79, 95% CI (0.58–1.08), Z = 1.46, P = 0.143] in the ICG group compared with the control group. Meanwhile, a subgroup analysis was performed, the result revealed no significant variance [RR = 0.79, 95%CI (0.58–1.08), Z=1.46, P=0.143] between the different locations (Figure 5).

Meta-analysis of lymph node detection

The test of heterogeneity was first conducted before performing a pooled analysis, and there was significantly

low heterogeneity across the five studies that reported lymph node detection outcomes (P = 0.192, $I^2 = 34.4\%$). A fixed-effects model was used to combine the pooled analysis, and the result revealed that this indicator was noticeably higher in the ICG group than in the control group [SMD=0.19, 95% CI (0.02-0.36), Z=2.16, P=0.031]. However, a subgroup analysis was not performed due to the small number of enrolled studies (Figure 6).

Meta-analysis of operation duration

The test of heterogeneity was first conducted before performing a pooled analysis, and there was obviously high heterogeneity (P = 0.000, $I^2 = 79.9\%$) across the nine studies that reported operation duration. A random-effect was used to do the pooled analysis. The result revealed that there was no statistically significant difference among these studies (SMD = -0.07, 95% CI (-0.30-0.15), Z = 1.53, P = 0.126). However, a subgroup analysis was not conducted because of the same distribution (Figure 7).

Meta-analysis of hospitalization time

The test of heterogeneity was first conducted before performing a pooled analysis, and the result showed that there was obviously high heterogeneity (P = 0.000, $I^2 = 76,3\%$) among these studies. A random-effect model was chosen to combine, and the pooled analysis showed that hospitalization time in the



ICG group was considerably decreased (SMD = -0.31, 95% CI (0.54–0.08), Z = 5.96, P = 0.000). A subgroup analysis was not carried out due to the small number of included studies coming from America/Europe (Figure 8).

Meta-analysis of intraoperative bleeding

The test of heterogeneity was first examined before performing a pooled analysis, and the result showed that there was moderate heterogeneity (P = 0.021, $I^2 = 59.7\%$) among these studies. Consequently, a pooled analysis was carried out using a random-effect model. The result showed that there was no statistically significant difference between the

ICG group and the control group [SMD = -0.16, 95% CI (-0.35-0.04), Z = 1.54, P = 0.122]. A subgroup analysis was not carried out in this meta-analysis since intraoperative bleeding was distributed similarly across regions (Figure 9).

Sensitivity analysis for robustness of pooled analysis

The sensitivity analysis was conducted by the leave-one-out method to evaluate the robustness of the combined results (hospitalization time, operation duration, and intraoperative bleeding) in the study. The robustness of the hospitalization time may have been impacted if Wu.G.C. (21) was excluded from the

		Certa	inty assessr	nent				Sum	mary of	findings
						Overall	Study eve	nt rates	Relative	Anticipate
Participants (studies) Follow-up	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	certainty of evidence	With blank treatment	, With ICG	effect (95% CI)	Risk with blank treatment
Anastomo	tic leak	age								
2677 (10 RCTs)	serious ^a	not serious	not serious	not serious	none	⊕⊕⊕O Moderate	119/1375 (8.7%)	57/1302 (4.4%)	RR 0.50 (0.37 to 0.67)	87 per 1,000
Postopera	tive mo	orbidity								
1511 (8 RCTs)	serious ^a	not serious	not serious	not serious	none	⊕⊕⊕⊖ Moderate	89/828 (10.7%)	60/683 (8.8%)	RR 0.79 (0.58 to 1.08)	107 per 1,000
Lymph no	de dete	ction	_							
552 (5 RCTs)	serious ^a	not serious	not serious	not serious	none	⊕⊕⊕O Moderate	292	260		-
Operation	duratio	n				0000				
(9 RCTs)	seriousª	not serious	not serious	not serious	none	Moderate	972	819	-	-
Hospitaliza	ation tir	ne								
1500 (8 RCTs)	serious ^a	not serious	not serious	not serious	none	⊕⊕⊕O Moderate	823	677	-	-
Intraopera	ative ble	eding								
1318 (7 RCTs)	serious ^a	not serious	not serious	not serious	none	Moderate	675	643	-	-
B. There was n	o single or	double blind in ar	ny RCT.							
B Outcor № of partic (studie	o single or me tipants	double blind in ar Relative effect (95% Cl)	ny RCT.	pated absol	ute effects ((95% CI) Difference	Certai	nty	v	Vhat happen
a. There was n B N₂ of partic (studie Anaston	o single or me cipants es) notic	double blind in ar Relative effect (95% CI)	t Antici	pated absol	ute effects ((95% CI) Difference	Certai	nty	v	Vhat happer
a. Inere was n B Outcor № of partic (studie Anaston leakage № of partic 267 (10 RC	o single or cipants es) notic (AL) cipants: 7 Ts)	double blind in ar Relative effect (95% Cl) RR 0.50 (0.37 to 0.67)	Antici	pated absol 4. (3.2	ute effects (.3% 4 to 5.8) (?	(95% CI) Difference 1.3% fewer 5.5 fewer to 2.9 fewer)	Certai	nty DO ate ^a	W	V hat happer
B Outcor № of partic (studie Anaston leakage № of partic 267 (10 RC Postopei morbic № of partic (8 RC	o single or cipants (AL) (AL) (7 Ts) Tative dity L S)	double blind in ar Relative effect (95% CI) RR 0.50 (0.37 to 0.67) RR 0.79 (0.58 to 1.08)	Antici 8.7%	pated absol 4, (3.2 , 8, (6.2 t	ute effects (3% 4 to 5.8) (5% 2 (.5% 2 (.5% (295% CI) Difference 5.5 fewer to 2.9 fewer) 2.3% fewe 4.5 fewer to 0.9 more)	Certai Modera	nty DO DO DO Date ^a	W	What happen
B Outcor № of partic (studie Anaston leakage № of partic 267" (10 RC Postopel morbic № of partic 151" (8 RCI Lymph r detect № of partic 552 (5 RCI	ne ipants is) notic (AL) ipants: (AL) ipants: TS) ity ipants: L (S) ion ipants: S)	double blind in ar Relative effect (95% CI) (0.37 to 0.67) (0.58 to 1.08) -	Antici Antici 8.7%	4 , (3.2 (6.2 t	3% 3% 4 5 % 2 5% 2 2 3% 2 3% 2 3% 2 3% 2 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3	195% CI) Difference 1.3% fewei 2.3% fewei 2.3% fewei 4.5 fewer to 4.5 fewer to 4.5 fewer to 4.5 fewer to 0.9 more) MD 0.19 SI higher 0.26 higher to 0.36 higher)	Certai	nty DO Jate ^a DO Jate ^a	v	Vhat happer
a. Inere was no B Outcor № of partic (studie Anaston leakage 267' (10 RC Postoper morbic № of partic 151' (8 RC] Lymph r detect Ne of partic 552 (5 RC] Operation of Ne of partic 179' (9 RC]	o single or me ipants ss) notic (AL) (AL) (ipants: TS) rative lity ipants: L iso ipants: [s] Juration ipants: TS) Juration ipants: TS Juration ipants: TS Juration ipants: TS Juration ipants: TS Juration ipants: TS Juration ipants: TS Juration Isa Juration TS Juration Isa Juration TS Juration Isa Juration Juration TS Juration Juration Juration Juration Juration Juration Juration Juration Juration Juration Juration Juration TS Juration Juration TS Juration Juration Juration TS Juration Juration TS Juration Juration TS Juration Juration TS Juration Juration TS Juration Juration TS Juration Juration TS Juration Ju	double bilnd in ar Relative effect (95% Ci) (0.37 to 0.67) (0.58 to 1.08) - -	Antici Antici 8.7% 10.7%	9 ated absol 4 (3.2 8 (6.2 t	ute effects (.3% 4 to 5.8) 4 .5% (.5%	195% CI) Difference 1.3% fewer 5.5 fewer to 2.3% fewer 2.3% fewer 3.3% fewer 0.2 higher 0.2 higher 0.3 higher 0.3 higher 0.3 higher 0.3 higher 0.3 higher 0.3 higher	Certai	nty 200 atca 200 atca 200 atca	v.	What happen
B Outcor № of partic (studie Anaston leakage № of partic 267" (10 RC Postopel morbic № of partic 151" (8 RC Lymph r Lymph r Lymph r Lymph r Coperation c № of partic 179" (9 RC Hospitalizat № of partic 1500 (8 RC	o single or me :pants :s) notic (AL) ipants: T T ipants: ipants: ipants: fs) uration ipants: fs) uration ipants: fs) S S S	double blind in ar Relative effect (95% CI) RR 0.50 (0.37 to 0.67) RR 0.79 (0.58 to 1.08) - - -	ANY RCT. Antici AnticiAntici Anti	4 . (3.2 (6.2 t	ute effects (3% 4 (3) 5% 2 (1) 5% 2 (1) 5% 2 (1) 5% 2 (1) 5% 2 (1) 5% 2 (1) 5% 2 (1) 5% 5% 5% 5% 5% 5% 5% 5% 5% 5%	95% CI) Difference 1.3% fewei 5.5 fewert 2.9 fewer) 2.3% fewei 4.4.5 fewert to 0.9 more) MD 0.19 SI Digher 0.3 lower to 0.3 lower to 0.15 higher) 0.3 lower to 0.54 lower to	Certal Certal Modera Certal	nty	v	Mhat happer
a. Inere was n B Outcor No of partic (studie Anaston leakage 267' (10 RC Postopen morbic Ne of partic 151: (8 RCT Lymph r detect Ne of partic 552 (5 RCT Ne of partic Ne of partic Ne of partic Ne of partic Ne of partic 1591 (7 RCT Ne of partic 1311 (7 RCT Ne of partic	o single or ne ipants ip) notic (AL) ipants: TS) Tative lity ipants: TS) ipants: SS) ion time ipants: SS) rative ipants: SS) SS) ipants: SS) SS) ipants: SS) SS) SS) SS) SS) SS) SS) SS	double bilnd in ar Relative effect (95% Ci) RR 0.50 (0.37 to 0.67) RR 0.79 (0.58 to 1.08) - - - -	Antici Antici 8.7% 10.7%	4 (3.2 , 8 (6.2 t	ute effects (.3% 4 to 5.8) 2 .5% 2 .5% (.5%	195% CI) Difference 1.3% fewei 1.3% fewei 2.3% fewei 2.3% fewei 3.3% fewei 4.5 fewert to 0.3 more) Difference .3% fewei .3% fewei .3% fewei .3% fewei .3.5 higher .0.3 lower to .3.5 higher) MD 0.07 SS lower .3.4 lower to .0.4 higher) MD 0.16 SS lower .35 lower to	Certail Certail Modera Certail Modera Certail Modera Modera Certail Modera Certail Modera Certail Modera Certail Modera Certail Certail Modera Certail Certail Modera Certail Cert	nty	v 	What happer
a. Inere was no B Outcor No of partic (studie Anaston leakage No of partic 267" (10 RC Postopel morbic No of partic 151" (8 RCI Lymph r detect 552 (5 RCI Operation c Ne of partic 752 (9 RCI Ne of partic 150" (9 RCI Hospitalizat Ne of partic 150" (150" (17 RCI *The risk in effect of the	o single or me .:pants .:pa	double bilnd in ar Relative effect (95% CI) RR 0.50 (0.37 to 0.67) (0.58 to 1.08) - - - - - - vention group on (and its 95%,	Antici 8.7% 10.7%	9 4 (3.2 8 (6.2 t	ute effects (.3% (to 5.8) 4 .5% 2 .5% 2 . (. (. (. (. (. (. (. (195% CI) Difference 1.3% fewel 1.3% fewel 2.3% fewel 2.3% fewel 4.5 fewert to 0.9 more) IMD 0.19 SF higher 0.36 higher) 0.36 higher) MD 0.07 SE lower 0.36 lower to 0.56 lower to 0.54 lower to 0.75 lower to 0.76 higher) on the assis	Certai Certai Certai Certai Modera Modera Certai Modera Certai	nty	v	What happer
a. Inere was no B Outcor No of partic (studie Anaston leakage No of partic 267" (10 RC Postopel morbic No of partic 151" (8 RC Lymph r Lymph r Lymph r Lymph r 152" (9 RC No of partic 179" (9 RC Hospitalizat No of partic 1500 (8 RC Hospitalizat No of partic 1500 (8 RC 1500 (8 RC 1500 (8 RC) 1500 (8 RC) 1500 (150	o single or me :pants (AL) (JL)	double bilnd in ar Relative effect (95% CI) RR 0.50 (0.37 to 0.67) RR 0.79 (0.58 to 1.08) - - - - - - - - - - - - -	A Antici Antici 8.7% 10.7% - - - - - - - - - - - - - - - - - - -	pated absol	ute effects (.3% 4 to 5.8) (?) .5% 2 o 11.6) (?) - (?)	95% CI) Difference 1.3% fewei 1.3% fewei 2.9 fewer) 2.3% fewei 4.4.5 fewer to 0.9 more) MD 0.19 SC 1.0% fewei 0.2 higher to 0.36 higher) MD 0.07 SC 1.00 outgets 1.00 outgets 0.15 higher) MD 0.30 SC 1.54 lower to 0.35 lower to 0.36 lower to 0.37 lower to 0.38 lower to 0.39 lower to 0.30 lower to 0.30 lower to	Certai	nty	Darison gro	Mat happer

Level of quality of evidence: (A) GRADE evidence profile; (B) Summary table of findings.

study, but there were no opposing results (estimated SMD = -0.19, 95% CI: -0.31-0.08; Figure 10A). According to the sensitivity analysis of operation duration, Tsang Y.P. (25)'s exclusion from the study may have an impact in this study but not the opposite way around (estimated SMD = -0.16, 95% CI: -0.33-0.01; Figure 10B).

In addition, the sensitivity analysis of intraoperative bleeding (Figure 10C) demonstrated that the robustness and reliability of the pooled analysis would not be significantly impacted by any study. Finally, the pooled analysis was generally reliable and robust to some degree according to all the sensitivity analysis findings.



Contour-enhanced funnel plot to detect the potential source of publication bias

The counter-enhanced funnel plots were used to investigate the cause of publication bias, which contours represent statistically significant conventional milestones (P < 0.01, P < 0.05, P < 0.1, or P > 0.1). The contour-enhanced funnel plots of hospitalization time (Figure 11A), operative duration (Figure 11B), and intraoperative bleeding (Figure 11C), all missing RCTs were within the region of low statistical significance (P >0.1), which suggested that the asymmetry of the funnel plots was due to publication bias.



Risk ratio (RR) forest plot of postoperative morbidity and subgroup analysis of postoperative morbidity. (A): Forest plot of postoperative morbidity. (B): Subgroup analysis of postoperative morbidity.

Discussion

With the rapid progress of the modern minimally invasive techniques, the efficacy of laparoscopic colorectal surgery in the treatment of CRC has been confirmed (29-31). The surgeon would observe the abdomen clearly, peel off the lesion, and detect lymph

nodes effectively under the laparoscopy. Meanwhile, due to the potential of laparoscopy to reduce postoperative pain and promote the recovery of digestive function, the impact on the abdominal cavity becomes small. Furthermore, laparoscopy makes the images larger, the surgery more precise, and decreases intraoperative bleeding and surgical injuries (7, 32, 33). However, there are still



many difficulties in laparoscopic colorectal cancer, among which the main difficulty is to accurately determine the anastomosis blood flow during the operation. The primary cause of AL is the insufficient anastomotic blood flow during surgery. AL can be reduced if the operation program is revised based on anastomotic blood supplies in time (34). Currently, the perfusion of the digestive segment during laparoscopy mainly depends on the surgeon's subjective opinion, such as monitoring the color of the anastomosis and observing the incision margin, etc. There is a possibility of AL due to errors in judgment objectively (35). Furthermore, it is still a difficulty to detect lymph nodes completely in laparoscopic colorectal surgery. It is essential to evaluate the quality of surgery by detecting lymph nodes thoroughly in operation, especially for lymph nodes, which may





be ignored by using standard dissection protocols based on experience. Therefore, it is urgent to find out a technique that can accurately perform laparoscopic surgery and improve the effectiveness of surgical therapy while guiding and displaying anastomosis blood flow and lymph node detection in real time throughout the entire operation process. Therefore, it will be an important technological breakthrough to find a method that can guide and determine anastomosis blood flow and lymph node detection for laparoscopic colorectal surgery. ICG is a mildly toxic fluorescent substance that has been used in colorectal surgery more and more in recent years to monitor intestinal perfusion and visualize the surgical area, thus the incidence of AL would effectively reduce (36, 37). From 1998 to 2003, Kudszus et al. enrolled 402 patients in a control group without ICG who had colorectal surgery and a test group of patients who underwent ICG-assisted surgery from 2003 to 2008. The test group suggested that patients with poor perfusion underwent reanastomosis with the proximal bowel free, and the final





duration. (C): Sensitivity analysis of intraoperative bleeding.

percentage of AL was observed in both the test and control groups of 7.5% (15/201) and 3.5% (7/201), which indicated that ICG reduced the incidence of AL (38). The use of ICG in colorectal anastomosis procedures is increasing, and all of them have shown good results (37, 39, 40). The application of ICG provides a new option for lymphatic tracing technology (41, 42). Lymph nodes can be detected by ICG tracing up to 65.5%–100% for CRC, which helps guide lymph node dissection and raise the probability of having more positive lymph nodes (31, 43–46). The study by Nishigori et al. found that ICG altered lymph node dissection in 23.5% (4/21) of cases, and all nodes >5 mm in diameter were identified (47).

It was found that the use of ICG in laparoscopic colorectal surgery reduced AL, enhanced lymph node detection, and reduced hospitalization time. ICG assesses anastomotic blood flow more objectively before and after intestinal anastomosis in laparoscopic colorectal surgery and reduces the incidence of AL, which is consistent with the findings of Jafari MD et al. (38). Meanwhile, ICG has some advantages in lymph node tracing, such as the ability to precisely locate the distribution of metastatic lymph nodes and anterior lymph nodes, particularly extra-regional lymph nodes, and guide intraoperative lymph node dissection, improve lymph node detection rate after surgery, and reduce the number of missed positive lymph nodes (48, 49). Furthermore, ICG can precisely locate the lesion with less intraoperative trauma during laparoscopic colorectal surgery to reduce the hospitalization time. In this study, there was no statistical difference in the postoperative morbidity,



intraoperative bleeding, and operation duration between the two groups, which suggested that the application of ICG did not affect the surgical operation and postoperative recovery of the patients. In conclusion, the use of ICG in laparoscopic colorectal surgery is reliable and efficient, with the primary benefits of improving lymph node detection, reducing AL, and shortening hospitalization time.

Although strict inclusion and exclusion criteria for the metaanalysis literature were established, the following issues remain: (i) the quantity of articles was insufficient and the included literature's quality was average; (ii) although the inclusion studies were RCTs, not all of them mentioned the use of blinding; (iii) some indicators have a significant degree of heterogeneity when combined, which could affect the article's results; and (iv) according to the findings of the subgroup analysis, regional differences in AL outcomes may exist. These factors may have an impact on the final conclusions, which must be validated further by a large sample, multicenter, prospective randomized controlled trials.

Conclusively, ICG is dependable and effective in laparoscopic colorectal surgery, and it can be used to precisely locate the tumor and thoroughly clear the lymph node area intraoperatively, as well as to determine the blood supply to the intestine at the anastomosis, which has important practical value for reducing AL and improving lymph node detection.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

Author contributions

JD performed the search and drafted the manuscript. WH and YL performed the data extraction. TY and KX analyzed the data. XL and TX designed the study and amended the original draft. YL, WH, TY and KX equally involved and equally contributed into the study conduction. All authors contributed to the article and approved the submitted version.

Funding

This study is supported by the National Natural Science Foundation of China (No. 81860854, 82260936) and the National Natural Science Foundation of China's Post Grant Fund (No. 2018YFC170610512).

Acknowledgment

We are grateful to the authors for providing detailed data for this meta-analysis, as well as to all colleagues in this study for their hard work.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* (2021) 71(3):209–49. doi: 10.3322/caac.21660

2. Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. *Science* (1993) 260 (5109):812–6. doi: 10.1126/science.8484121

3. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. *Chin Med J (Engl)* (2021) 134(7):783–91. doi: 10.1097/CM9.000000000001474

4. Moris D, Tsilimigras DI, Machairas N, Merath K, Cerullo M, Hasemaki N, et al. Laparoscopic synchronous resection of colorectal cancer and liver metastases: A systematic review. *J Surg Oncol* (2019) 119(1):30–9. doi: 10.1002/jso.25313

5. Fujii S, Akagi T, Inomata M, Katayama H, Mizusawa J, Ota M, et al. Transitional impact of short- and long-term outcomes of a randomized controlled trial to evaluate laparoscopic versus open surgery for colorectal cancer from Japan clinical oncology group study JCOG0404. *Ann Gastroenterol Surg* (2019) 3(3):301-9. doi: 10.1002/ags3.12245

6. Zelhart M, Kaiser AM. Robotic versus laparoscopic versus open colorectal surgery: towards defining criteria to the right choice. *Surg Endosc* (2018) 32(1):24–38. doi: 10.1007/s00464-017-5796-2

7. Yu Y, Zhang CC, Zhou JM, Yan ZL. Application of near-infrared fluorescence laparoscopic technique in gastric cancer surgery. *Chin J Gen Surg* (2019) 03:280–2. doi: 10.3760/cma.j.issn.1007-631X.2019.03.031

8. Nagata K, Endo S, Hidaka E, Tanaka J, Kudo SE, Shiokawa A. Laparoscopic sentinel node mapping for colorectal cancer using infrared ray laparoscopy. *Anticancer Res* (2006) 26(3b):2307–11.

9. Keller DS, Ishizawa T, Cohen R, Chand M. Indocyanine green fluorescence imaging in colorectal surgery: overview, applications, and future directions. *Lancet Gastroenterol Hepatol* (2017) 2(10):757–66. doi: 10.1016/S2468-1253(17)30216-9

10. Huang CM, Zheng ZH, Chen QY. The application of indocyanine green near infrared imaging in laparoscopic radical gastrectomy of gastric cancer: Chinese expert consensus (2019 edition). *Chin J Pract Surg* (2020) 40(02):139–44. doi: 10.19538/j.cjps.issn1005-2208.2020.02.02

11. Li Y, Li XX, Wang Q, Wang ZQ, Yao HW. Chinese Expert consensus on the application of indocyanine green near infrared imaging in laparoscopic colorectal cancer surgery (2021 edition). *Chin J Pract Surg* (2021) 41(10):1098–103+110. doi: 10.19538/j.cjps.issn1005-2208.2021.10.03

12. Fang CH, Wang XY, Liu YY. Guidelines for application of computerassisted indocyanine green molecular fluorescence imaging in diagnosis and surgical navigation of liver tumors (2019). *Chin J Pract Surg* (2019) 39(07):641– 50+54. doi: 10.19538/j.cjps.issn1005-2208.2019.07.01

13. Mangano A, Masrur MA, Bustos R, Chen LL, Fernandes E, Giulianotti PC. Near-infrared indocyanine green-enhanced fluorescence and minimally invasive colorectal surgery: Review of the literature. *Surg Technol Int* (2018) 33:77–83.

14. Alekseev M, Rybakov E, Shelygin Y, Chernyshov S, Zarodnyuk I. A study investigating the perfusion of colorectal anastomoses using fluorescence

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

angiography: results of the FLAG randomized trial. *Colorectal Dis* (2020) 22 (9):1147–53. doi: 10.1111/codi.15037

15. De Nardi P, Elmore U, Maggi G, Maggiore R, Boni L, Cassinotti E, et al. Intraoperative angiography with indocyanine green to assess anastomosis perfusion in patients undergoing laparoscopic colorectal resection: results of a multicenter randomized controlled trial. *Surg Endosc* (2020) 34(1):53–60. doi: 10.1007/s00464-019-06730-0

16. Park JH, Moon HS, Kwon IS, Yun GY, Lee SH, Park DH, et al. Usefulness of colonic tattooing using indocyanine green in patients with colorectal tumors. *World J Clin Cases* (2018) 6(13):632–40. doi: 10.12998/wjcc.v6.i13.632

17. Ishii M, Hamabe A, Okita K, Nishidate T, Okuya K, Usui A, et al. Efficacy of indocyanine green fluorescence angiography in preventing anastomotic leakage after laparoscopic colorectal cancer surgery. *Int J Colorectal Dis* (2020) 35(2):269–75. doi: 10.1007/s00384-019-03482-0

18. Bonadio L, Iacuzzo C, Cosola D, Cipolat Mis T, Giudici F, Casagranda B, et al. Indocyanine green-enhanced fluorangiography (ICGf) in laparoscopic extraperitoneal rectal cancer resection. *Updates Surg* (2020) 72(2):477–82. doi: 10.1007/s13304-020-00725-6

19. Kin C, Vo H, Welton L, Welton M. Equivocal effect of intraoperative fluorescence angiography on colorectal anastomotic leaks. *Dis Colon Rectum* (2015) 58(6):582–7. doi: 10.1097/DCR.0000000000320

20. Reng P, Zhang Y, Tao JX, Shen RH, Wang T. The role of indolecine green imaging in reducing anastomotic leakage after laparoscopic radical resection of colorectal cancer. *J Clin Surgery* (2018) 26(10):754–6. doi: 10.3969/j.issn.1005-6483.2018.10.011

21. Wu GC, Li J, Xu W, Guo C, Xu FM. Application of indolecine green imaging in prevention of anastomotic leakage after laparoscopic radical resection of colorectal cancer. J Western Med (2021) 33(07):1035–8. doi: 10.3969/j.issn.1672-3511.2021.07.020

22. Zhang JF, Gao XX, Wu XL, Ma HQ, Hu XH, Wang ZZ, et al. Safety, feasibility and clinical value of indolyanine green fluorescence guided lymph node dissection for 253 groups of colorectal cancer. *J Pract Med* (2021) 37(12):1598–602. doi: 10.3969/j.issn.1006- 5725.2021.12.017

23. Zhou SC, Tian YT, Wang XW, Zhao CD, Ma S, Jiang J, et al. Application of indocyanine green-enhanced near-infrared fluorescence-guided imaging in laparoscopic lateral pelvic lymph node dissection for middle-low rectal cancer. *World J Gastroenterol* (2019) 25(31):4502–11. doi: 10.3748/wjg.v25.i31.4502

24. Su H, Wu H, Bao M, Luo S, Wang X, Zhao C, et al. Indocyanine green fluorescence imaging to assess bowel perfusion during totally laparoscopic surgery for colon cancer. *BMC Surg* (2020) 20(1):102. doi: 10.1186/s12893-020-00745-4

25. Tsang YP, Leung LA, Lau CW, Tang CN. Indocyanine green fluorescence angiography to evaluate anastomotic perfusion in colorectal surgery. *Int J Colorectal Dis* (2020) 35(6):1133–9. doi: 10.1007/s00384-020-03592-0

26. Ge L, Zhou HT, Su H, Xu Z, Luo S, Liang JW, et al. Application of indocyanine green fluorescence imaging technique in evaluation of intestinal perfusion in totally laparoscopic left hemicolectomy. *Zhonghua Wai Ke Za Zhi* (2021) 59(5):338–42. doi: 10.3760/cma.j.cn112139-20200619-00473

27. Foo CC, Ng KK, Tsang J, Wei R, Chow F, Chan TY, et al. Colonic perfusion assessment with indocyanine-green fluorescence imaging in anterior resections: a propensity score-matched analysis. *Tech Coloproctol* (2020) 24(9):935–42. doi: 10.1007/s10151-020-02232-7

28. Jing DS, Yuan PF, Dong SJ. Effect of indocyanine green fluorescence imaging on rehabilitation and postoperative complications of patients undergoing laparoscopic colon cancer resection. *Jiangxi Med J* (2021) 56 (10):1718–20. doi: 10.3969/j.issn.1006-2238.2021.10.041

29. Liberale G, Vankerckhove S, Caldon MG, Ahmed B, Moreau M, Nakadi IE, et al. Fluorescence imaging after indocyanine green injection for detection of peritoneal metastases in patients undergoing cytoreductive surgery for peritoneal carcinomatosis from colorectal cancer: A pilot study. *Ann Surg* (2016) 264 (6):1110–5. doi: 10.1097/SLA.00000000001618

30. Yang Z, Min ZJ, Quan. YJ. Advances in the application of fluoroscopic laparoscopic techniques in abdominal tumor surgery. *Chin J Pract Surg* (2018) 38 (09):1077–80. doi: 10.19538/j.cjps.issn1005-2208.2018.09.28

31. Liberale G, Vankerckhove S, Galdon MG, Larsimont D, Ahmed B, Bouazza F, et al. Sentinel lymph node detection by blue dye versus indocyanine green fluorescence imaging in colon cancer. *Anticancer Res* (2016) 36(9):4853–8. doi: 10.21873/anticanres.11048

32. Xi HQ, Jian YB, Chen ZD, Li JY. Preliminary application of indocyanine green fluorescence real-time imaging in lymph node dissection for radical thyroid cancer. *Chin J Endocrine Surg* (2019) 03:219–23. doi: 10.3760/cma.j.issn.1674-6090.2019.03.010

33. Li WB, Zhang JY, Bao JW, Liu Z. Indocyanine green-mediated near-infrared light detection technique in surgical resection of gallbladder cancer. *J Pract Hepatol* (2019) 22(04):573–6. doi: 10.3969/j.issn.1672-5069.2019.04.031

34. Lei ZH, FW G, Zhao X, Jiang KY. A preliminary study on the application of indocyanine green fluorescence imaging technique in laparoscopic cholecystectomy. *J Hepatopancreatobiliary Surgery* (2019) 31(09):522–5. doi: 10.11952/j.issn.1007-1954.2019.09.003

35. Karliczek A, Harlaar NJ, Zeebregts CJ, Wiggers T, Baas PC, van Dam GM. Surgeons lack predictive accuracy for anastomotic leakage in gastrointestinal surgery. *Int J Colorectal Dis* (2009) 24(5):569–76. doi: 10.1007/s00384-009-0658-6

36. Jafari MD, Lee KH, Halabi WJ, Mills SD, Carmichael JC, Stamos MJ, et al. The use of indocyanine green fluorescence to assess anastomotic perfusion during robotic assisted laparoscopic rectal surgery. *Surg Endosc* (2013) 27(8):3003–8. doi: 10.1007/s00464-013-2832-8

37. Kawada K, Hasegawa S, Wada T, Takahashi R, Hisamori S, Hida K, et al. Evaluation of intestinal perfusion by ICG fluorescence imaging in laparoscopic colorectal surgery with DST anastomosis. *Surg Endosc* (2017) 31(3):1061–9. doi: 10.1007/s00464-016-5064-x

38. Kudszus S, Roesel C, Schachtrupp A, Höer JJ. Intraoperative laser fluorescence angiography in colorectal surgery: a noninvasive analysis to reduce

the rate of anastomotic leakage. *Langenbecks Arch Surg* (2010) 395(8):1025–30. doi: 10.1007/s00423-010-0699-x

39. Gröne J, Koch D, Kreis ME. Impact of intraoperative microperfusion assessment with pinpoint perfusion imaging on surgical management of laparoscopic low rectal and anorectal anastomoses. *Colorectal Dis* (2015) 17 Suppl 3:22–8. doi: 10.1111/codi.13031

40. Jafari MD, Wexner SD, Martz JE, McLemore EC, Margolin DA, Sherwinter DA, et al. Perfusion assessment in laparoscopic left-sided/anterior resection (PILLAR II): a multi-institutional study. *J Am Coll Surg* (2015) 220(1):82–92.e1. doi: 10.1016/j.jamcollsurg.2014.09.015

41. Omar MA, Redwan AA, Mahmoud AG. Single-incision versus 3-port laparoscopic cholecystectomy in symptomatic gallstones: A prospective randomized study. *Surgery* (2017) 162(1):96-103. doi: 10.1016/ j.surg.2017.01.006

42. Han HJ, Kang CM. Reduced port minimally invasive distal pancreatectomy: single-port laparoscopic versus robotic single-site plus one-port distal pancreatectomy. *Surg Endosc* (2019) 33(4):1091–9. doi: 10.1007/s00464-018-6361-3

43. Noura S, Ohue M, Seki Y, Tanaka K, Motoori M, Kishi K, et al. Feasibility of a lateral region sentinel node biopsy of lower rectal cancer guided by indocyanine green using a near-infrared camera system. *Ann Surg Oncol* (2010) 17(1):144–51. doi: 10.1245/s10434-009-0711-2

44. Hirche C, Mohr Z, Kneif S, Doniga S, Murawa D, Strik M, et al. Ultrastaging of colon cancer by sentinel node biopsy using fluorescence navigation with indocyanine green. *Int J Colorectal Dis* (2012) 27(3):319–24. doi: 10.1007/s00384-011-1306-5

45. Watanabe J, Ota M, Suwa Y, Ishibe A, Masui H, Nagahori K. Evaluation of lymph flow patterns in splenic flexural colon cancers using laparoscopic real-time indocyanine green fluorescence imaging. *Int J Colorectal Dis* (2017) 32(2):201–7. doi: 10.1007/s00384-016-2669-4

46. Andersen HS, Bennedsen ALB, Burgdorf SK, Eriksen JR, Eiholm S, Toxværd A, et al. *In vivo* and ex vivo sentinel node mapping does not identify the same lymph nodes in colon cancer. *Int J Colorectal Dis* (2017) 32(7):983–90. doi: 10.1007/s00384-017-2777-9

47. Nishigori N, Koyama F, Nakagawa T, Nakamura S, Ueda T, Inoue T, et al. Visualization of Lymph/Blood flow in laparoscopic colorectal cancer surgery by ICG fluorescence imaging (Lap-IGFI). *Ann Surg Oncol* (2016) 23 Suppl 2:S266–74. doi: 10.1245/s10434-015-4509-0

48. Currie AC. Intraoperative sentinel node mapping in the colon: Potential and pitfalls. *Eur Surg Res* (2019) 60(1-2):45–52. doi: 10.1159/000494833

49. Liberale G, Bohlok A, Bormans A, Bouazza F, Galdon MG, El Nakadi I, et al. Indocyanine green fluorescence imaging for sentinel lymph node detection in colorectal cancer: A systematic review. *Eur J Surg Oncol* (2018) 44(9):1301–6. doi: 10.1016/j.ejso.2018.05.034